Patent expiry and costs for anti-cancer medicines for clinical use : expiry and costs anti-cancer medicines
Godman, Brian and Wild, Claudia and Haycox, Alan (2017) Patent expiry and costs for anti-cancer medicines for clinical use : expiry and costs anti-cancer medicines. Generics and Biosimilars Initiative journal. pp. 1-3. ISSN 2033-6403 (In Press)
|
Text (Godman-etal-GABI-2017-Patent-expiry-and-costs-for-anti-cancer-medicines-for-clinical)
Godman_etal_GABI_2017_Patent_expiry_and_costs_for_anti_cancer_medicines_for_clinical.pdf Accepted Author Manuscript Download (235kB)| Preview |
Abstract
Drs Brian Godman, Claudia Wild and Alan Haycox review the paper by Venkatesan et al on the patent expiry of (non-) tyrosine kinase inhibitors.
Creators(s): | Godman, Brian, Wild, Claudia and Haycox, Alan; | Item type: | Article |
---|---|
ID code: | 60241 |
Keywords: | anti cancer medicines, medicine patents, tyrosine kinase inhibitors, Pharmacy and materia medica, Pharmacology, Toxicology and Pharmaceutics(all) |
Subjects: | Medicine > Pharmacy and materia medica |
Department: | Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences |
Depositing user: | Pure Administrator |
Date deposited: | 20 Mar 2017 10:18 |
Last modified: | 05 Jan 2021 01:59 |
Related URLs: | |
URI: | https://strathprints.strath.ac.uk/id/eprint/60241 |
Export data: |
CORE (COnnecting REpositories)